FutureHouse Science-First Head Start

This reveals that science first is already becoming a crowded entry point, not an open beachhead. FutureHouse has already turned that story into a real product surface, with a web app, an API, biology specific agents, and workflows for literature review, target discovery, and chemistry planning, while Core Automation is still using its own lab as the first proving ground and has no public product yet. That gives FutureHouse a head start with scientists, pharma teams, and research partners.

• FutureHouse launched its platform on May 1, 2025 with four science agents, including tools for deep literature review, prior art checks, and chemistry planning. It also exposes these agents through an API, which matters because research groups can plug them into recurring workflows instead of treating them like a one off demo.
  2 futurehouse
• By November 2025, FutureHouse said demand had moved beyond research buzz into commercial pull, with inbound interest from executives at 6 of the top 10 pharma companies and enough usage pressure to require higher rate limits. That is the difference between having a narrative and already owning buyer attention in a niche.
  3 futurehouse
• Core Automation is pointed at a broader long term prize. It is trying to automate its own research loop first, then expand into external software and possibly model layer commercialization. But in the science wedge specifically, Benchling and Lila Sciences show that buyers also value domain workflows, lab system fit, and integrated infrastructure, not just raw model capability.
  1 sacra 4 sacra 5 sacra

The next step is likely a split market. FutureHouse and similar players can lock up life sciences demand with domain specific products and partnerships, while Core Automation will need to jump from internal research automation to a broader horizontal work automation story where it is not forced to win scientist trust first. If that jump works, science becomes a launch case, not the whole company.